Ubika Research has initiated coverage of Zecotek Photonics Inc. (CVE:ZMS), a leading manufacturer of medical imaging technology. Zecotek is transitioning from a Research and Development company to a revenue-generating entity with profitability anticipated by the second half of 2017.
The company (TSXV:ZMS; Frankfurt: W1I, OTCPK: ZMSPF) is a photonics technology company developing high-performance scintillation crystals, photo detectors, positron emission tomography scanning technologies, 3D auto-stereoscopic displays, 3D metal printing, and lasers for applications in medical, high-tech and industrial sectors. Founded in 2004, Zecotek operates three divisions: Imaging Systems, Optronics Systems and 3D Display Systems with labs located in Canada, Korea, Russia, Singapore and U.S.A. The management team is focused on building shareholder value by commercializing over 50 patented and patent pending novel photonic technologies directly and through strategic alliances, the European Organization for Nuclear Research (Switzerland), Beijing Opto-Electronics Technology Co. Ltd. (China), NuCare Medical Systems (South Korea), the University of Washington (United States), and National NanoFab Center (South Korea). For more information visit www.zecotek.com and follow @zecotek on Twitter.
To find out more about Zecotek Photonics Inc., please visit the company’s Investor Hub.
Ubika Research/SmallCapPower has received compensation to provide analyst research coverage. For full disclosure please visit here >>.
